PT  - JOURNAL ARTICLE
AU  - Jennings, Mariela V
AU  - Lee, Hyunjoon
AU  - Rocha, Daniel B
AU  - Bianchi, Sevim B
AU  - Coombes, Brandon J
AU  - Crist, Richard C
AU  - Faucon, Annika
AU  - Hu, Yirui
AU  - Kember, Rachel L
AU  - Mallard, Travis T
AU  - Niarchou, Maria
AU  - Poulsen, Melissa N
AU  - Straub, Peter
AU  - Urman, Richard D
AU  - Walsh, Colin G
AU  - ,
AU  - Davis, Lea K
AU  - Smoller, Jordan W
AU  - Troiani, Vanessa
AU  - Sanchez-Roige, Sandra
TI  - Identifying high-risk comorbidities of short and long-term opioid prescription use
AID  - 10.1101/2021.11.23.21266717
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.23.21266717
4099  - http://medrxiv.org/content/early/2021/11/24/2021.11.23.21266717.1.short
4100  - http://medrxiv.org/content/early/2021/11/24/2021.11.23.21266717.1.full
AB  - Background Electronic health records (EHR) are useful tools for understanding complex medical phenotypes, but they have been underutilized for opioid use disorders (OUD). Patterns of prescription opioid use might provide an objective measure of OUD risk.Methods We extracted data for over 2.6 million patients across three health registries (Vanderbilt University Medical Center, Mass General Brigham, Geisinger) between 2005 and 2018. We defined three groups based on levels of opioid exposure: No Prescription, Minimal Exposure (2 prescriptions within 90 days at least once, but never 3 prescriptions <90 days apart), and Chronic Exposure (≥10 opioid prescriptions in a year), and compared them to the full registries and to patients with OUD diagnostic codes. We extracted demographic and clinical characteristics known to co-occur with OUD, including psychiatric and substance use disorders, pain-related diagnoses, HIV, and hepatitis C.Results The prevalence of substance (alcohol, tobacco, cannabis) use disorders was higher in patients with OUD and Chronic Exposure than those with No Prescription or Minimal Exposure. Patients in the OUD and Chronic Exposure groups had more psychiatric (anxiety, depression, schizophrenia, bipolar disorder) and medical comorbidities (pain, hepatitis C, HIV) than those in the Minimal Exposure group. Notably, patients in the Minimal Exposure group had different comorbidity profiles (higher rates of substance use and psychiatric disorders, more pain conditions) than those in the Unscreened or No Prescription groups, highlighting the value of including opioid exposure in studies of OUD.Conclusions Long-term opioid prescription use may serve as an additional tool to characterize OUD risk.Competing Interest StatementDr. Urman reports unrelated funding and/or fees from the NIH, AHRQ, NSF, Medtronic, Merck, AcelRx, Heron, Acacia, and Pfizer. Dr. Smoller is a member of the Leon Levy Foundation Neuroscience Advisory Board and has received honoraria for an internal seminar at Biogen, Inc and Tempus Labs. He is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. He is also a member of the Scientific Advisory Board of Sensorium Therapeutics.Funding StatementMVJ, SBB and SSR were supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526), SBB is also supported by P50DA037844, SSR is also supported by NIDA DP1DA054394. HL is supported by funds from NIH 1R01MH118233-01. BJC is supported by funds from NIMH R01 MH121924. ABF was supported by the Training Program On Genetic Variation And Human Phenotypes Training Grant (T32GM080178). MP is supported by funds from NIDA K01DA04993. TTM is supported by funds from NIH T32HG010464. CGW is supported by funds from NIMH R01 MH118233, R01 MH121455, R01 MH120122, R01 MH116269, DoD MSRC W81XWH-10-2-0181, and the FDA WO2006. VT and RCC are supported by funds from NIDA R01DA044015 and a grant from the Pennsylvania Department of Health. The PsycheMERGE consortium is supported by NIMH R01 MH118233 (JWS, LKD). The project using VUMC data was supported by CTSA award No. UL1TR000445 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We acquired Institutional Review Board approval (VUMC: 201767, MGB: 2018P002642); consent was not required for review of deidentified medical records. The Geisinger Institutional Review Board deemed this research exempt because all variables were extracted and summarized using an approved data broker.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in the present study are available to researchers at the cited institutions. Code used to determine group membership available here: https://github.com/sanchezroigelab/OUD_spectrum_PsycheMERGE https://github.com/sanchezroigelab/OUD_spectrum_PsycheMERGE